Introduction {#sec1}
============

The neurohypophyseal hormone oxytocin is anxiolytic (Neumann and Slattery, [@ref37]) and plays an essential role in human pro-social behaviors (MacDonald and MacDonald, [@ref33]). Administering exogenous oxytocin reduces anxiety and anxious behaviors in rodents (Uvnäs-Moberg *et al.*, [@ref57]; Windle *et al.*, [@ref61]; Rotzinger *et al.*, [@ref47]; Slattery and Neumann, [@ref53]) and humans (Heinrichs *et al.*, [@ref19]; Goodin *et al.*, [@ref16]) and inhibits the concomitant physiological stress response (Grippo *et al.*, [@ref18]; Neumann *et al.*, [@ref36]; de Oliveira *et al.*, [@ref8]). Similarly, humans with higher endogenous levels of oxytocin report less anxiety; this has been observed in both adults (Scantamburlo *et al.*, [@ref50]) and children (Carson *et al.*, [@ref5]). However, researchers are only beginning to elucidate the biological mechanisms---neuroendocrine, autonomic, genetic and epigenetic---through which oxytocin affects anxiety. A more refined understanding of these processes, particularly in how they interact within the same individual, is needed.

Oxytocin's physiological basis in anxiolysis stems, in part, from its control over the autonomic nervous system. Multiple studies have demonstrated a close connection between oxytocin and the parasympathetic branch of the autonomic nervous system. Administration of oxytocin has been shown to increase high-frequency heart rate variability (HF-HRV; Kemp *et al.*, [@ref24]; Norman *et al.*, [@ref38]), a measure of parasympathetic cardiac control which is consistently attenuated across a range of anxiety disorders (Chalmers *et al.*, [@ref6]). Oxytocin modulates HF-HRV through interactions with the solitary-vagal complex, comprised of the dorsal motor nucleus and the nucleus of the solitary tract. The solitary-vagal complex receives oxytocinergic projections from the paraventricular nucleus of the hypothalamus. Oxytocin receptor activity in the solitary-vagal complex affects cardiac control and has been shown to increase parasympathetic tone by slowing the heart rate during blood pressure challenges (Higa *et al.*, [@ref20]). Notably, oxytocin-mediated changes in cardiac activity have not been observed through the sympathetic branch of the autonomic nervous system (Higa *et al.*, [@ref20]) nor does oxytocin typically affect sympathetic nervous system activity (Gamer and Büchel, [@ref14]), suggesting that oxytocin's physiological effects stem from exclusive interactions with the parasympathetic nervous system.

Further contributing to this autonomic, anxiolytic pathway is oxytocin's connection to the central nucleus of the amygdala. The central nucleus regulates the physiological fear response through numerous projections to the brainstem (LeDoux *et al.*, [@ref31]), including the solitary-vagal complex. Central amygdala neural activity is consistently implicated in studies of HF-HRV (Thayer *et al.*, [@ref54]), and lesioning the central amygdala suppresses parasympathetic cardiac activity during stress (Roozendaal *et al.*, [@ref46]). A wealth of research has directly implicated the amygdala as a target of oxytocin-induced anxiolysis. The central amygdala is rich in oxytocin receptors, and it has been shown that oxytocin release in this region contributes to the suppression of fear-conditioned behaviors (Bale *et al.*, [@ref2]; Landgraf and Neumann, [@ref30]; Viviani *et al.*, [@ref58]). In addition, pathways linking the central amygdala to the brainstem, including the solitary-vagal complex, are modulated by oxytocin, and oxytocin administration decreases fear-related behaviors in rodents via these pathways (Viviani *et al.*, [@ref58]). In humans, intranasal oxytocin administration modulates amygdala blood oxygen level dependent (BOLD) response, most often observed as a reduction in amygdala reactivity to aversive stimuli (Kirsch *et al.*, [@ref25]; Domes *et al.*, [@ref9]; Labuschagne *et al.*, [@ref28]). Similarly, this attenuation of amygdala reactivity has also been observed as a function of participants own endogenous (plasma) oxytocin levels (Lancaster *et al.*, [@ref29]). Finally, oxytocin's amygdalar connection is also reflected in structural differences in the human amygdala: participants with lower endogenous oxytocin levels and carriers of an oxytocin receptor gene *(OXTR)* single nucleotide polymorphism risk-allele showed increased gray matter density within the amygdala (Tost *et al.*, [@ref56]; Andari *et al.*, [@ref1]; Lancaster *et al.*, [@ref29]), pointing toward an enduring relationship between the oxytocinergic system and the subcortical brain structure.

Many of oxytocin's effects appear to be mediated by its receptor, encoded by *OXTR* (Kusui *et al.*, [@ref27]). Importantly, the oxytocin system is partially regulated through epigenetic mechanisms, including DNA methylation. Increased methylation of a DNA methylation control region in the *OXTR* promoter has been associated with decreased expression of the receptor, reflecting a downtuning of the oxytocin system (Kusui *et al.*, [@ref27]; Gregory *et al.*, [@ref17]). In the same way that differences in plasma oxytocin and genetic variability in *OXTR* explain anxiogenesis using either a behavioral or neural endophenotype, *OXTR* methylation is associated with amygdala BOLD response. In a recent paper, greater *OXTR* methylation in this promoter region (reflecting a dampened oxytocin system) was associated with an increase in participants' amygdala reactivity to aversive faces (Puglia *et al.*, [@ref43]). However, it remains unclear whether this methylation-associated amygdala dysregulation extends into other biological systems and whether it manifests also in autonomic dysregulation.

In the current study, we sought to better characterize the relationship between epigenetic variability in the oxytocin system and anxiety-related endophenotypes in order to improve our mechanistic understanding of oxytocin's contribution to anxiolysis. In light of previous work, which has identified relationships between oxytocin, the parasympathetic nervous system and the subcortical brain structure, we expected that greater *OXTR* methylation would be associated with decreased parasympathetic nervous system activity and increased central amygdala gray matter. Further, given the central amygdala's autonomic connections to the brainstem, we expected that the gray matter density of the central amygdala might mediate the relationship between *OXTR* methylation and the parasympathetic nervous system.

Methods {#sec2}
=======

Participants {#sec3}
------------

Structural neuroimaging data, blood samples and cardiovascular data were acquired from 95 participants from the Charlottesville, VA, area (46 males, 49 females; mean age, 21.09; age s.d. = 2.62). Participants in this study were recruited from a larger imaging genetics study and received \$75 total for their participation. Eligible participants were Caucasian; between the ages of 18 and 30; had no history of head trauma, seizures or electroconvulsive therapy; were not currently taking stimulants, sedatives or antipsychotic medications; and had no neurological or uncontrolled medical conditions. Neuroimaging and blood collection were performed during one session, and the cardiovascular assessment was completed in a follow-up session on a separate day. All participants provided informed consent as overseen by the University of Virginia Institutional Review Board. Due to equipment failures, usable psychophysiological data were not acquired for 10 participants (1 additional participant experienced an equipment failure mid-experiment, but were included in the analyses due to usable baseline/resting data). Additionally, six participants' data were excluded due to extreme values, including methylation (two participants) and cardiovascular \[HF-HRV/pre-ejection period (PEP); four participants\] values which were \>2 s.d.s from the mean, leaving a final sample of 79 participants with usable data (35 males, 44 females; mean age, 20.89; age s.d. = 2.40).

Blood collection and DNA extraction {#sec4}
-----------------------------------

Blood samples were collected at the University of Virginia Fontaine Research Park between 10:00 and 11:00 am. For epigenetic analyses, 8 ml of whole blood were collected in mononuclear cell separation tubes. The tubes were spun at 1800 relative centrifugal force for 30 min, according to product protocol. The Gentra Puregene Blood Kit (Qiagen, Valencia, CA) was then used to lyse mononuclear cells and extract DNA. Extracted DNA was stored at −20°C.

Epigenotyping {#sec5}
-------------

The epigenotyping procedures and materials are similar to those employed in Jack *et al.*[@ref21]). Using Invitrogen kit MECOV50 (Carlsbad, CA), 200 ng of extracted DNA was subject to bisulfite conversion. Subsequently, 20 ng/uL of bisulfite converted DNA was used as a polymerase chain reaction (PCR) template with a Pyromark PCR kit (Qiagen, Valencia, CA) and 0.2 uM/uL primers (5′-TTGAGTTTTGGATTTAGATAATTAAGGATT-3′) and (5′-biotin-AATAAAATACCTCCCACTCCTTATTCCTAA-3′). Three identical PCR machines (C1000 Thermal Cycler, Biorad, Hercules, CA) amplified samples in triplicate. Amplification of the 116bp fragment-containing site −934 within a DNA methylation control region in the *OXTR* promoter (hg19, chr3:8,810,729-8,810,845) was achieved using the following cycling conditions \[step 1: (95°C/15 min)/1 cycle, step 2: (94°C/30 s, 56°C/30 s, 72°C/30 s)/50 cycles, step 3: (72°C/10 min)/1 cycle, step 4: hold at 4°C\]. PCR conditions were determined using a set of standards for site −934 at 0, 25, 50, 75 and 100% methylated {theoretical *vs* experimental Pearson's correlation of 0.998 \[95% confidence interval (95% CI): 0.995--0.999\], *P* \< 0.001}. Successful PCR amplification was confirmed using agarose gel electrophoresis for each sample and replicate. Pyrosequencing was performed on a Pyromark Q24 with PyroMark Gold Q24 Reagents (Qiagen, Valencia, CA) using primer (5′-AGAAGTTATTTTATAATTTTT-3′). Samples were randomized to control for plate and run variability. The average deviation from the mean was ±1.58%. Epigenotypes reported are an average of the three replicates.

Anatomical imaging {#sec6}
------------------

Structural imaging was performed on a Siemens Magnetom Trio 3T scanner using a 12-channel head coil. High-resolution T1-weighted gradient echo images (MPRAGE, TR = 1900 ms, TE = 2.53 ms, FOV = 250 mm, resolution = 1 × 1 × 1 mm, FA = 9°, 176 total volumes) were acquired for each participant.

Cardiovascular data acquisition {#sec7}
-------------------------------

In a subsequent session (mean time elapsed post-scan = 99.98; s.d. = 137.34 days)**,** participants were invited into a laboratory in the University of Virginia Psychology Department to undergo a cardiovascular assessment of autonomic nervous system activity. Participants were asked to avoid consuming caffeine or other stimulants for 3 h prior to the study. All cardiovascular data were recorded using a Bionex impedance cardiograph from MindWare Technologies (Gahanna, OH) using a sampling rate of 1000 Hz. Six spot electrodes were placed across each participant's thorax to acquire electrocardiogram (ECG) and impedance cardiography data, according to prior recommendations (Qu *et al.*, [@ref44]; Sherwood *et al.*, [@ref52]). Proprietary BioLab software was used for data acquisition and analysis; participants' physiological data were analyzed in one minute segments, and each segment was visually inspected for artifacts and corrected when applicable.

Resting/baseline and stress task {#sec8}
--------------------------------

To collect resting cardiovascular data, participants were instructed to sit in a upright but relaxed position while passively observing nature scenes and sounds for 6 min (prior research has shown that the absence of any stimulus is aversive to participants; Wilson *et al.*, [@ref60]). Data collection commenced when participants indicated they felt sufficiently comfortable and relaxed, and concluded after 6 min had elapsed. For the stress portion of the study, we adapted the math test from the Trier Social Stress Test (Kirschbaum *et al.*, [@ref26]). For a recording duration of 2 min, we asked participants to count down in increments of 13 from 1022 as quickly as possible. When participants made a mistake, they were told to start from the beginning. If they hesitated for \>3 s before responding, they were instructed to \`\`please respond faster."

Body mass index {#sec9}
---------------

Participants' height and weight were recorded during the second session, and body mass index (BMI) was computed as participants' height in centimeters divided by their squared weight in kilograms. BMI was not associated with any of our variables of interest and thus is not discussed further.

Statistical analyses {#sec10}
--------------------

Behavioral data were analyzed using SPSS version 23 (Armonk, NY: IBM Corp.), using two-tailed tests and an alpha criterion of 0.05.

### HF-HRV {#sec11}

We estimated parasympathetic nervous activity using HF-HRV from ECG data. Employing the HRV analysis module (Mindware Technologies), the interbeat interval series was estimated using the peak-to-peak distance between the ECG R-waves. This series was detrended and end-tapered, and a Fast Fourier transformation was applied to calculate spectral power. This was then integrated over the high-frequency band of 0.12--0.40 Hz and values were log-transformed to obtain HF-HRV for each participant in units of ms^2^. This measurement of HF-HRV is also commonly referred to as respiratory sinus arrhythmia, as it corresponds to respiration-linked variance in the heart period from the activity of cardiac vagal neurons (Bertson *et al.*, [@ref4]). Higher HF-HRV reflects greater parasympathetic activity. To validate that our measurement of HF-HRV was unobscured by respiration artifacts, we followed the recommendation of Laborde *et al.* ([@ref28a]) and confirmed that participants' spontaneous respiratory rates fell within the range corresponding to the derivation of HF-HRV. To accomplish this, we estimated participants' respiration using impedance cardiography (Ernst *et al.*, [@ref12]) and confirmed for each measurement of HF-HRV that participants' peak respiratory power fell within the 0.12--0.40 Hz frequency band (i.e. a respiratory rate of 7--24 breath cycles/min).

### Pre-ejection period {#sec12}

We estimated sympathetic nervous activity using PEP from the first derivative of the impedance waveform (dZ/dt) of the impedance cardiography data. PEP was measured as the time period in milliseconds between the onset of ventricular depolarization (the Q wave from the ECG channel) and the opening of the aortic valve (the B point on the dZ/dt wave). Using the IMP analysis module (Mindware Technologies), the Q wave was automatically pinpointed at the onset of the R wave (Berntson *et al.*, [@ref3]), while a previously validated algorithm estimated the B point as a function of the R-dZ/dt peak interval (Lozano *et al.*, [@ref32]). PEP is an inverse measure of sympathetic activity as a greater time period reflects *less* sympathetic nervous system activity.

### Voxel-based morphometry {#sec13}

FSL-VBM v1.1 (FMRIB software; Douaud *et al.*, [@ref10]) was used to estimate gray matter volume of the central amygdala. Participants' high resolution structural scans were tissue segmented and non-linearly normalized into Montreal Neurological Institute (MNI) space, creating a study-specific gray matter template. Participants' native gray matter masks were fitted to the template and multiplied by a Jacobian determinant to correct for the non-linear spatial transformation. These corrected images were then smoothed using a Gaussian kernel with a sigma of 2 mm. Non-parametric permutation testing (*n* = 5000 permutations) using threshold-free cluster enhancement (*P* \< 0.05, corrected for multiple comparisons) was used to identify gray matter volume differences associated with participants' *OXTR* methylation levels. Using methylation as our predictor of interest, we conducted a whole-brain analysis and a priori region of interest (ROI) analysis of the central amygdala using a probabilistic mask of the central amygdala: voxels with \>50% probability of belonging to the centromedial nucleus of the bilateral amygdala as specified by the Juelich Histological Atlas (Eickhoff *et al.*, [@ref11]) were included in this mask. Given that prior literature has found differential effects of oxytocin in subregions of the amygdala (Gamer *et al.*, [@ref15]), we conducted a final ROI analysis using a probabilistic mask of the basolateral amygdala to examine whether effects of *OXTR* methylation on amygdala gray matter were specific to the central nucleus.

![Higher *OXTR* methylation is associated with lower baseline HF-HRV. Greater methylation levels of *OXTR* are associated with low resting HF-HRV, measured in milliseconds squared (ms^2^).](nsy086f1){#f1}

![Gray matter density is associated with *OXTR* methylation and baseline HF-HRV. **(A)***OXTR* methylation positively is associated with gray matter in the right central amygdala, *peak voxel xyz = 22, −10, −8, cluster extent = 7 voxels, P = 0.032; cluster displayed on coronal slice at z = −8*. **(B)** Higher percent methylation is associated with increased gray matter volume, *AU, arbitrary units.***(C)** Gray matter volume is in turn associated with lower baseline log HF-HRV*,* ms^2^, milliseconds squared*.*](nsy086f2){#f2}

Results {#sec14}
=======

Summary statistics for subjective reports, HRV/PEP and *OXTR* methylation {#sec15}
-------------------------------------------------------------------------

For both the baseline measurement and the math test stress-elicitation, participants indicated their stress level on a 100-point scale that ranged from 0 (very relaxed) to 100 (very stressed). Participants indicated that they were generally relaxed during baseline/resting measurement (M = 21.19, s.d. = 17.69). Participants' subjective report of feelings of stress during the math test were modest (M = 58.80, s.d. = 17.69) but were still significantly different from the midpoint, t(75) = 3.02, *P* = 0.003. Resting HRV (M = 6.79, s.d. = 1.08) was significantly higher than HRV during stress (M = 6.31, s.d. = 1.02), t(77) = 3.79, *P* = 0.0003. Similarly, resting PEP (M = 125.56, s.d. = 9.85) was significantly greater than PEP during stress (M = 120.38, s.d. = 12.40), t(77) = 5.81, *P* = 1.31E-7. These results confirm that participants' parasympathetic activity decreased during stress, while their sympathetic activity increased during stress. Across participants, the average percent methylation at site −934 was M = 46.64 (s.d. = 5.63). Methylation did not correlate with age, r(77) = −0.11, *P* = 0.352 or differ by sex, t(77) = 1.62, *P* = 0.110. Furthermore, central amygdala volumes did not correlate with age, r(77) = 0.06, *P* = 0.583 or differ by sex t(77) = 0.16, *P* = 0.875. Similarly, HF-HRV and PEP variables did not correlate with age (all *P*s \> 0.21) or differ by sex (all *P*s \> 0.09).

*OXTR* methylation is associated with decreased autonomic nervous system activity {#sec16}
---------------------------------------------------------------------------------

As predicted, *OXTR* methylation was significantly inversely associated with resting HF-HRV, such that participants with high levels of methylation had lower resting HF-HRV, r(77) = −0.26, *P* = 0.021 ([Figure 1](#f1){ref-type="fig"}). In contrast, *OXTR* methylation was not associated with HF-HRV during the stress task, r(76) = --0.07, *P* = 0.559. Similarly, there was no significant relationship between methylation and PEP at rest, r(77) = --0.04, *P* = 0.740, or during stress, r(76) = 0.06, *P* = 0.615.

*OXTR* methylation is associated with increased central amygdala gray matter volume {#sec17}
-----------------------------------------------------------------------------------

A priori ROI analysis using a mask of the bilateral central amygdala revealed a significant cluster in the right amygdala ([Figure 2A](#f2){ref-type="fig"}): participants with higher *OXTR* methylation levels had greater percentage of gray matter in this region (7 contiguous voxels, peak voxel coordinates *x = 22, y = −10, z = −8*), *P* = 0.032 ([Figure 2B](#f2){ref-type="fig"}). In a second step, we tested for associations across the whole brain; this exploratory analysis did not reveal any additional associations between *OXTR* methylation and gray matter density. In a final step, to probe for the specificity of the association with the central amygdala, we reconducted our analysis using a mask of the basolateral amygdala. Similar to the exploratory whole-brain analysis, we did not find any associations with *OXTR* methylation.

To test for a relationship between the methylation-associated gray matter differences and our physiological outcomes, we extracted participants' individual gray matter estimates from the significant cluster identified in the central amygdala. We then used these values to run bivariate correlations. Gray matter densities were significantly inversely associated with HRV at rest, r(77) = *−*0.32, *P* = 0.004 ([Figure 2C](#f2){ref-type="fig"})*.* This negative correlation illustrates that participants with increased central amygdala gray matter densities had decreased resting HF-HRV, which parallels the relationship between gray matter and *OXTR* methylation. In contrast, gray matter density was not significantly associated with any other physiological measure, i.e. PEP at rest: r(77) = −0.10, *P* = 0.360; PEP during stress: r(76) = −0.08, *P* = 0.486; and HF-HRV during stress: r(76) = −0.08, *P* = 0.488.

*OXTR* methylation and autonomic nervous system activity is mediated by central amygdala gray matter density {#sec18}
------------------------------------------------------------------------------------------------------------

Given the three-way association between *OXTR* methylation, central amygdala gray matter volume and resting HF-HRV, we tested mediation (model illustrated in [Figure 3](#f3){ref-type="fig"}) using a bias-corrected bootstrapping procedure (Preacher and Hayes, [@ref42]) with 5000 samples. With this procedure, the test of the indirect effect is significant if the 95% CI does not contain zero. Indeed, we observed evidence of mediation (indirect effect = −0.0156; 95% CI, −0.040 to −0.002), such that gray matter density of the central amygdala mediated the relationship between *OXTR* methylation and HF-HRV.

![Central amygdala gray matter density mediates the relationship between *OXTR* methylation and HF-HRV. [Figure 3](#f3){ref-type="fig"} illustrates the mediational relationship between *OXTR* methylation, parasympathetic nervous system activity (log HF-HRV) and central amygdala gray matter. Path c reflects the total effect of the predictor on the dependent variable, while path c' reflects the direct effect and paths ab reflect the indirect effect of the mediator, *ns = not significant, ^\*^ corresponds to a* P *value smaller than the significance level of 0.05.*](nsy086f3){#f3}

Discussion {#sec19}
==========

Our results demonstrate that *OXTR* methylation is negatively associated with resting parasympathetic tone and that this relationship is mediated by structural differences in the central amygdala. High levels of *OXTR* methylation have previously been associated with an increase of amygdala reactivity to aversive stimuli (Puglia *et al.*, [@ref43]), a pattern of neural reactivity that is supported by studies investigating the effects of exogenous (Kirsch *et al.*, [@ref25]) and endogenous oxytocin (Lancaster *et al.*, [@ref29]). Because oxytocin signaling has been implicated in anxiolysis, a downtuning of the oxytocin system via DNA methylation of *OXTR* is assumed to have anxiogenic consequences, but its specific relationship with the autonomic nervous system had not yet been characterized. Here, we provide evidence that epigenetic modification of the human oxytocin system is associated with the parasympathetic branch of the autonomic nervous system and suggest this may occur mechanistically through gray matter density differences in the central amygdala.

Notably, our finding that *OXTR* methylation predicts amygdala gray matter volume is consistent with our previous research demonstrating that low plasma oxytocin was associated with increased gray matter in the right central amygdala (Lancaster *et al.*, [@ref29]). Here, we have replicated this structural association using *OXTR* methylation: participants with high *OXTR* methylation---which is thought to reflect a dampening or reduced efficiency of the endogenous oxytocin system (Kusui *et al.*, [@ref27])---is associated with increased gray matter in the right central amygdala. This conceptual replication, and the regional specificity of the findings to the central nucleus, reinforces the importance of central amygdala structure in the relationship between oxytocin and negative emotionality. Furthermore, the current findings are generally aligned with our previous work on *OXTR* methylation and amygdala BOLD response (Puglia *et al.*, [@ref43]). Increased activity within the amygdala (which is likely to contribute to increased gray matter density through dendritic spinogenesis, Keifer *et al.*, [@ref23]; Mitra *et al.*, [@ref35], and synaptogenesis, Kassem *et al.*, [@ref22]) is a marker of anxious temperament in humans (Schwartz *et al.*, [@ref51]) and non-human primates (Fox *et al.*, [@ref13]; Oler *et al.*, [@ref39]); we have previously shown that participants with high levels of *OXTR* methylation show increased amygdalar activity to negative stimuli (Puglia *et al.*, [@ref43]). Together, these findings illustrate the synergy of multiple bodily systems (autonomic, oxytocinergic, limbic structure and function) substrative of an anxiety phenotype.

Interestingly, in our sample, *OXTR* methylation was associated only with the parasympathetic branch of the autonomic nervous system and only at rest. This may indicate that *OXTR* methylation is not associated with stress-elicited vagal withdrawal but rather with tonic vagal output under baseline conditions. Tonic parasympathetic cardiac control is regulated by vagal preganglionic neurons projecting from the solitary-vagal complex (Machhada *et al.*, [@ref34]), which is innervated by the central nucleus of the amygdala (Saha *et al.*, [@ref49]), a pathway that is modulated by oxytocin (Higa *et al.*, [@ref20]; Viviani *et al.*, [@ref58]). While previous work has shown an oxytocin peptide-mediated increase in vagal outflow under blood pressure challenges (Higa *et al.*, [@ref20]), our results suggest that epigenetic modification of *OXTR* is more relevant for baseline/tonic vagal efferent action. Porges [@ref40]) and Porges *et al.* ([@ref41]) have argued that fast-acting vagal withdrawal during stress (the \`vagal brake') is evolutionarily adaptive for responding to dynamic threats, enabling the fight or flight response. If vagal withdrawal were epigenetically regulated by the availability of oxytocin receptors, this would limit the ability of the autonomic nervous system to quickly and flexibly alter physiological responses during stress. Instead, our findings suggest that epigenetic influence over the oxytocin system contributes to autonomic function in a manner that is more tonic than dynamic; this is supported by our finding that this relationship is mediated by neural structural differences, which are not transiently occurring.

Future research will be needed to better interpret our findings. For one, we examined putative anxiety endophenotypes (based on prior literature), but we did not link these directly to self-reported anxiety in the current study, nor did we explore the influence of covariates beyond sex and age. Using a more comprehensively phenotyped sample could clarify, for instance, how HF-HRV is linked to anxiogenesis through deficiencies in emotion regulation, as has been previously reported (Thayer and Lane, [@ref55]; Williams *et al.*, [@ref59]). The availability of additional behavioral data could also rule out potential confounds, such as the influence of alcohol consumption on physiology (Quintana *et al.*, [@ref45]) and, thus, should be a goal for subsequent research. Another factor which limits the interpretation of our findings is the current knowledge gap concerning how epigenetic modifications of *OXTR* reflect functional changes in oxytocin system structure and function in humans. Methylation of the region we assayed on *OXTR* is known to downregulate transcription of the gene (Kusui *et al.*, [@ref27]; Gregory *et al.*, [@ref17]), but it is unclear whether methylation and resultant changes in expression of OXTRs are distributed across all oxytocin-relevant tissues (Lancaster *et al.*, [@ref29]). There is some evidence (Dadds *et al.*, [@ref7]) that methylation levels are inversely associated with plasma oxytocin levels---potentially implicating a widespread impact on the oxytocin system---but more recent findings suggest this association might be modulated by sex and psychiatric conditions (Rubin *et al.*, [@ref48]). Our understanding of how epigenetic influences on the oxytocin system contribute to anxiogenesis will benefit from future work that addresses these issues.

Conclusion {#sec20}
==========

In this study, we have provided the first evidence that *OXTR* methylation is associated with tonic parasympathetic function and that this association is mediated by gray matter differences within the central amygdala. These findings highlight the importance of epigenetic regulation of the oxytocin system in anxiety and fear-related processes and suggest a physiological mechanism through which it may operate in humans.
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